Periungual pyogenic granulomas after ravulizumab therapy in a child with acute myelomonocytic leukemia treated with hematopoietic stem cell transplant.
Helena IznardoIvan López-TorijaLaura Mateu-ArromPablo Escribano-SanzLluís PuigEsther RoéPublished in: Pediatric dermatology (2024)
Development of periungual pyogenic granulomas (pPGs) has been associated with several systemic treatments, including retinoids, taxanes, epidermal growth factor receptor inhibitors, and vascular endothelial growth factor inhibitors. We present the case of an 8-year-old girl with a personal history of acute myelomonocytic leukemia treated with a haploidentical hematopoietic stem cell transplant who developed pPGs 2 months after starting ravulizumab. Ravulizumab is a monoclonal antibody directed against C5 protein. No previous reports of pPGs development have been described with ravulizumab.
Keyphrases
- hematopoietic stem cell
- epidermal growth factor receptor
- vascular endothelial growth factor
- monoclonal antibody
- liver failure
- bone marrow
- respiratory failure
- acute myeloid leukemia
- drug induced
- tyrosine kinase
- advanced non small cell lung cancer
- aortic dissection
- mental health
- stem cell transplantation
- intensive care unit
- peripheral blood
- newly diagnosed
- low dose
- small molecule
- protein protein
- cord blood
- mesenchymal stem cells
- high dose
- binding protein
- adverse drug